arrow
S

Silvy Laporte

Université Jean Monnet
H指数:47
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Enoxaparin for the treatment of placenta-derived fetal growth restriction (GROWTH): an open-label multicenter randomized trial

依诺肝素治疗胎盘源性胎儿生长受限(GROWTH):一项开放标签多中心随机试验

2026-07-170
PRE
Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial

癌症相关静脉血栓栓塞症延长抗凝治疗期间临床相关出血的预测因素(API-CAT):一项随机、非劣效性试验的事后分析

2025-12-060
PRE
Prevention of Hemorrhage After Implantation of Mechanical Circulatory Support With a Purified Von Willebrand Factor Concentrate: results of the early terminated randomized controlled PHAM trial

机械循环支持植入术后出血的预防:使用纯化血管性血友病因子浓缩物的早期终止随机对照PHAM试验结果

2025-10-080
PRE
Prevention of perioperative venous thromboembolism: 2024 guidelines from the French Working Group on Perioperative Haemostasis (GIHP) developed in collaboration with the French Society of Anaesthesia and Intensive Care Medicine (SFAR), the French Society of Thrombosis and Haemostasis (SFTH) and the French Society of Vascular Medicine (SFMV) and endorsed by the French Society of Digestive Surgery (SFCD), the French Society of Pharmacology and Therapeutics (SFPT) and INNOVTE (Investigation Network On Venous ThromboEmbolism) network

围术期静脉血栓栓塞症的预防:法国围术期止血工作组(GIHP)2024年指南,由其与法国麻醉与重症医学学会(SFAR)、法国血栓与止血学会(SFTH)和法国血管医学学会(SFMV)合作制定,并得到法国消化外科学会(SFCD)、法国药理学与治疗学学会(SFPT)以及INNOVTE(静脉血栓栓塞症研究网络)的支持。

2024-10-220
OAAI
Effect of weight-adjusted intermediate-dose versus fixed-dose prophylactic anticoagulation with low-molecular-weight heparin on venous thromboembolism among noncritically and critically ill patients with COVID-19: the COVI-DOSE trial, a multicenter, randomised, open-label, phase 4 trial
2023-06-0110
OAAI
Frequency and predictors for chronic thromboembolic pulmonary hypertension after a first unprovoked pulmonary embolism: Results from PADIS studies

首次非诱因性肺栓塞后慢性血栓栓塞性肺动脉高压的频率和预测因素: PADIS研究的结果

2022-12-017
OAAI
Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism A Randomized Trial
CHEST
IF8.6
2022-03-0196
PRE
Frequency and risk factors for Chronic Thromboembolic Pulmonary Hypertension after a first unprovoked Pulmonary Embolism: results from PADIS-studies
2021-11-250
PRE
Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study
2021-11-0542
OAAI
Prothrombotic disturbances of hemostasis of patients with severe COVID-19: A prospective longitudinal observational study

严重新型冠状病毒肺炎患者的血栓前止血障碍: 一项前瞻性纵向观察研究

2021-01-0135
OAAI